Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam

Journal of Global Antimicrobial Resistance
Nadia CastaldoMatteo Bassetti

Abstract

Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T.

Citations

Mar 2, 2018·Expert Review of Anti-infective Therapy·Daniele Roberto GiacobbeUNKNOWN ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva)
Jan 17, 2019·Current Opinion in Infectious Diseases·Paola Del GiacomoMario Tumbarello
Nov 19, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G NazzaroL Brambilla
Jun 8, 2018·Current Infectious Disease Reports·Lynn NguyenConan MacDougall
Nov 20, 2020·Critical Reviews in Food Science and Nutrition·Gilberto V de Melo PereiraCarlos R Soccol
Apr 10, 2021·Antimicrobial Resistance and Infection Control·Laura PuzniakAshley Enstone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.